8 April 2019

Polyneuron Pharmaceuticals AG, a developer of a new class of biodegradable glycopolymers for the treatment of autoimmune diseases, today announced the closing of an oversubscribed CHF22.5 million Series A financing. The round was led by Sofinnova Partners and co-led by New Enterprise Associates (NEA), with the participation of existing investors.

VISCHER advises Polyneuron in this transaction. The team includes Matthias Staehelin (Partner, Corporate M&A), Moritz Jäggy (Managing Associate, Corporate M&A) and Sebastian Flückiger (Associate, Corporate M&A).

Categories: Corporate and Commercial, Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk, Tax

You are currently offline. Some pages or content may fail to load.